NCT06679738

Brief Summary

Gall stone disease is more common in patients with cirrhosis. This association has been well established in different studies. Among the various factors which predispose a patient with gall stone disease to have associated liver cirrhosis, genetics also plays an important role. This study aims to do a genetic panel-based analysis of genes which are involved in cholestasis to find any association between liver cirrhosis and gall stone disease. Patients with history of gall stone or history of cholecystectomy done for gall stone disease will be evaluated for the presence of liver cirrhosis by fibroscan and ultrasonography. Those patients with cirrhosis and without cirrhosis will undergo a panel based genetic test for the common cholestasis genes and multivariate analysis will be done for variants associated with lithogenesis and cirrhosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 6, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 7, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

November 10, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

November 7, 2024

Status Verified

November 1, 2024

Enrollment Period

1.1 years

First QC Date

November 6, 2024

Last Update Submit

November 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Identification of genetic risk-variants associated with both GS and modulation of liver cirrhosis in patients with cirrhosis.

    Day 0

Secondary Outcomes (3)

  • Identification of genetic polymorphisms in bile-acid metabolism and enterohepatic circulation, associated with increased GS risk in patients with cirrhosis.

    Day 0

  • Identification of genetic polymorphisms in cholesterol metabolism pathway, associated with increased GS risk in patients with cirrhosis.

    Day 0

  • To study the association of UGT1A1 polymorphisms affecting bilirubin conjugation, with risk of GS in patients with cirrhosis.

    Day 0

Study Arms (5)

Cirrhosis with GSD

Cirrhosis with GSD

No cirrhosis with no GSD

No cirrhosis with no GSD

Cirrhosis with no GSD

Cirrhosis with no GSD

GSD with no cirrhosis

GSD with no cirrhosis

Cirrhosis with history of cholecystectomy for GSD

Cirrhosis with history of cholecystectomy for GSD

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* Patients \> 18 years of age. * Who have either gall stone disease or cirrhosis.

You may qualify if:

  • Patients \> 18 years of age.
  • Who has a GSD diagnosed by USG or have history of cholecystectomy for gall stone disease.
  • Who is a diagnosed case of cirrhosis by Fibroscan or USG (Cirrhosis including alcohol related cirrhosis, Hepatitis B, Hepatitis C, Wilsons disease, Hemochromatosis are excluded.

You may not qualify if:

  • Patients who have haemolytic anaemia
  • Patients who do not consent for genetic study
  • Patients who has a diagnosed cause for liver disease, including alcohol related cirrhosis, Hepatitis B, Hepatitis C, Wilsons disease, Hemochromatosis.
  • Inability to provide informed consent.
  • Cannot understand Hindi or English should be excluded since they will not be able to reply objectively to questionnaire.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

Location

Biospecimen

Retention: SAMPLES WITH DNA

Genetic Analysis

MeSH Terms

Conditions

Liver CirrhosisGallstones

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and SymptomsCholelithiasisBiliary Tract DiseasesCholecystolithiasisGallbladder DiseasesCalculiPathological Conditions, Anatomical

Central Study Contacts

Dr Ananthu Narayan S J, MD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 6, 2024

First Posted

November 7, 2024

Study Start

November 10, 2024

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

November 7, 2024

Record last verified: 2024-11

Locations